Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Context Therapeutics Inc. - Common Stock (NQ: CNTX )

0.8140 +0.0240 (+3.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 90,026
Open 0.8490
Bid (Size) 0.7855 (12)
Ask (Size) 0.8500 (6)
Prev. Close 0.7900
Today's Range 0.7828 - 0.8490
52wk Range 0.7700 - 2.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga

Performance

YTD
-31.60%
-31.60%
1 Month
-10.39%
-10.39%
3 Month
-44.25%
-44.25%
6 Month
-67.44%
-67.44%
1 Year
-29.83%
-29.83%

More News

Read More
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
From Context Therapeutics Inc.
Via GlobeNewswire
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics to Participate in Upcoming Investor Conferences in November
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
From Context Therapeutics Inc.
Via GlobeNewswire
Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight
Via InvestorPlace
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Via InvestorPlace
CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Announces $100 Million Private Placement
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
From Context Therapeutics Inc.
Via GlobeNewswire
CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.